Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 19INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Liver Failure × Clear all
NCT04617522 2026-02-11

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Gilead Sciences

Phase 1 Recruiting
30 enrolled

Neoplasm Metastasis, Liver Failure

NCT01452295 2013-12-04

Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion

Vital Therapies, Inc.

Phase 2/3 Withdrawn

Hepatitis, Alcoholic, Liver Failure, Liver Failure, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡